Unmet Need
- Fluorination is vital in drug discovery yet often costly and multi-step
- Existing routes are essentially de novo syntheses, relying on pre-decorated precursors and often forming elimination side-products
- The industry is in need for a single-step, site-selective method to stereoconvert substituted fluorinated piperidines late in the workflow.
Our Innovation
- Epimerization converting cis-fluorinated piperidines to trans in one step
- Late-stage, site-selective stereochemical editing applicable to drug analogues
- Selectivity enabled by stereoelectronic/electrostatic effects of fluorine
Advantages
- Single step access to desired diastereomer; avoids de novo syntheses
- High stereoselectivity, consistently high yields, broad substrate scope
- Readily available starting materials; compatible with med-chem diversification
Commercial Opportunity
We are seeking collaboration with pharmaceutical companies and drug discovery partners to apply the stereoconversion for lead optimization, rapid SAR, and candidate acceleration.
Contact in Yissum: Ariela Markel
